Previous close | 33.80 |
Open | 12.09 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 80.00 |
Expiry date | 2024-07-19 |
Day's range | 10.33 - 33.80 |
Contract range | N/A |
Volume | |
Open interest | 29 |
On June 17, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), executed a sale of 6,105 shares of the company. The transaction was filed on June 18, 2024, as reported in the SEC Filing. Following this transaction, the insider now owns 213,351 shares of Natera Inc.
AUSTIN, Texas, June 17, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.
AUSTIN, Texas, June 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 7:40 a.m. PT (10:40 a.m. ET).